Drug Development Stages
The journey from laboratory discovery to an approved psychedelic medicine takes 10–15 years on average. Here is what happens at each stage of the pipeline, how many companies are active at each phase, and what it means for patients.
Discovery
Researchers identify and validate potential drug candidates — often novel psychedelic analogues or prodrugs designed for improved safety, duration, or route of administration.
Typical Duration
2–5 years
Success Rate
~10% advance to preclinical
What Happens
Target identification, compound screening, medicinal chemistry optimisation, and initial in-vitro testing. For psychedelics, this often involves designing molecules with modified receptor selectivity or reduced hallucinogenic effects.
Preclinical
Candidate compounds are tested in laboratory and animal models to assess safety, toxicology, pharmacokinetics, and initial efficacy before any human exposure.
Typical Duration
1–3 years
Success Rate
~30% advance to Phase I
What Happens
ADME studies (absorption, distribution, metabolism, excretion), acute and chronic toxicology, formulation development, and IND-enabling studies. For psychedelics, abuse liability assessments and cardiovascular safety (5-HT2B) are critical.
Phase I
First-in-human studies in a small group of healthy volunteers (or sometimes patients) to evaluate safety, tolerability, and pharmacokinetics.
Typical Duration
6–18 months
Success Rate
~70% advance to Phase II
What Happens
Single ascending dose (SAD) and multiple ascending dose (MAD) studies. Determines the safe dosage range and identifies side effects. For psychedelic candidates, this often includes pharmacodynamic measures like subjective experience ratings.
Phase I/II
Combined early-stage trials that assess both safety and preliminary efficacy in a single study, common for psychedelic medicines where dosing and efficacy signals can be evaluated concurrently.
Typical Duration
1–2 years
Success Rate
~50% advance to Phase II/III
What Happens
Adaptive designs that start with dose-escalation in healthy volunteers and transition to efficacy assessment in patients. Particularly common in psychedelic drug development where the therapeutic model (single or few doses) differs from conventional daily dosing.
Phase II
Larger trials in patients with the target condition to evaluate efficacy, optimal dosing, and further characterise safety. Often the most informative stage for psychedelic candidates.
Typical Duration
1–3 years
Success Rate
~30% advance to Phase III
What Happens
Randomised, controlled trials (often placebo-controlled) in 50–300 patients. Dose-finding (Phase IIa/IIb) and proof-of-concept. For psychedelics, these trials must address blinding challenges due to the subjective effects of the active compound.
Phase II/III
Seamless trials that can transition from dose-finding to pivotal efficacy assessment, used when regulators and sponsors agree the programme is ready to generate registration-quality data.
Typical Duration
2–3 years
Success Rate
~50% advance to filing
What Happens
Adaptive designs with pre-specified interim analyses. If Phase II results meet criteria, the trial seamlessly expands into a registrational Phase III. Can significantly shorten overall development timelines.
Phase III
Large-scale pivotal trials designed to confirm efficacy and safety in a broader patient population. These provide the primary data for regulatory submissions.
Typical Duration
2–4 years
Success Rate
~60% lead to NDA filing
What Happens
Typically two adequate and well-controlled studies (or one large study with compelling results) in 300–3,000+ patients. Multi-site, often multi-national. For psychedelic medicines, REMS requirements and treatment-day logistics (monitoring periods, trained facilitators) are planned in detail.
NDA Filed / Regulatory Review
The sponsor submits a New Drug Application (NDA) to the FDA or equivalent filing to EMA/other regulators, requesting approval to market the medicine.
Typical Duration
10–18 months review
Success Rate
~85% of filed NDAs are approved
What Happens
Comprehensive submission of all clinical, preclinical, manufacturing, and labelling data. FDA conducts advisory committee review. For psychedelic medicines, REMS (Risk Evaluation and Mitigation Strategy) details are a key component — defining who can prescribe, where administration occurs, and monitoring requirements.
Approved
The medicine receives regulatory approval and can be prescribed to patients. Post-marketing requirements typically include Phase IV studies and ongoing pharmacovigilance.
Typical Duration
Ongoing
Success Rate
Marketed
What Happens
Commercial launch, formulary negotiations, provider education, and treatment centre establishment. Phase IV post-marketing surveillance and real-world evidence generation. For psychedelic medicines, training certified facilitators and establishing compliant treatment settings are unique post-approval challenges.
Explore the Pipeline
See which companies are at each stage of development and track their progress.
View All Drug Developers